Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04685993 · ClinicalTrials.gov registry record · Phase 2
A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
A Phase 2 study of NASH - Nonalcoholic Steatohepatitis, sponsored by Lipocine.
- Completed
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 10
- Study locations
NCT04685993 is a Phase 2 study of NASH - Nonalcoholic Steatohepatitis that has completed, run by Lipocine. The registered enrollment target is 25 participants, below the 268-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (91% lower). The trial reports 10 study locations across 6 states.
The verdict
NCT04685993, a Phase 2 study of NASH - Nonalcoholic Steatohepatitis, has completed, sponsored by Lipocine.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 10
- Study locations
Study Summary
This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men with NASH.
Conditions Studied
Interventions
- DRUG LPCN 1144
Study Locations (10)
Texas
- R&H Clinical Research - Katy
- Sun Research Institute - San Antonio
- Endeavor Clinical Trials - San Antonio
- Pioneer Research Soultions - Sugar Land
Utah
- Advanced Clinical Research - Gut Whisperer - Riverton
- Granger Medical Clinic - West Valley City
California
- Clinical Trials Research - Roseville
Florida
- Sensible Healthcare, LLC - Ocoee
Nevada
- Jubilee Clinical Research, Inc. - Las Vegas
Virginia
- Manassas Clinical Research Center - Manassas
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2020-11-11 |
| Est. Completion | 2022-03-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04685993
The ClinicalTrials.gov registry entry for NCT04685993 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 268-participant average among 27 other NASH - Nonalcoholic Steatohepatitis trials with a reported enrollment target (91% lower). The listed sponsor is Lipocine, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with NASH - Nonalcoholic Steatohepatitis appearing as the primary indexed condition, and to 1 intervention - of which LPCN 1144 is the first listed.
NCT04685993 reports 10 study locations spanning 6 distinct geographic areas - top geographies include Texas, Utah, California.
Frequently Asked Questions
What is clinical trial NCT04685993 about?
NCT04685993 is a clinical study titled "A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial". This is an open-label extension to Study LPCN 1144-18-002. The study is aimed at evaluating the safety and tolerability of LPCN 1144 in adult men with NASH.
What is the current status of trial NCT04685993?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2020-11-11. Estimated completion is 2022-03-01.
What conditions does trial NCT04685993 study?
This clinical trial studies the following conditions: NASH - Nonalcoholic Steatohepatitis.
What interventions are being tested in trial NCT04685993?
The interventions under investigation include: LPCN 1144 (DRUG).
Who is sponsoring clinical trial NCT04685993?
This trial is sponsored by Lipocine, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04685993 being conducted?
This trial has 10 study locations across California, Florida, Nevada, Texas, Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for NASH - Nonalcoholic Steatohepatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study to Evaluate Efficacy, Safety and Tolerability of HM15211(Efocipegtrutide) in Subjects
ACTIVE NOT RECRUITING · Phase 2
-
A Study of Efruxifermin in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH) (Symmetry)
ACTIVE NOT RECRUITING · Phase 2
-
Statins for the Treatment of NASH
ACTIVE NOT RECRUITING · Phase 2
-
Tocotrienol Against the Progression of End Stage Liver Disease
ACTIVE NOT RECRUITING · Phase 2
-
Phase 2a Study of HU6 in Subjects With Elevated Liver Fat and High BMI Volunteers
COMPLETED · Phase 2
-
A Study to Evaluate the Safety, Tolerability & Efficacy of MSDC-0602K in Patients With NASH
COMPLETED · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.